review punch scotti pt
va deliveri rais visibl biopharma backlog set
solid execut nois
move outperform price target
cadenc recoveri reliant scienc higher margin
color fundament focu call
bound clinic reiter outperform
inhibitor readi despit pandem
pandem may reset expect
report leav mark
jelmyto june launch pad commerci strategi tailor
time
report modest trial pushout
analyst certif import disclosur see
roughli expect ruc code still
expect juli
thought impact recoveri path
replant orchard maintain outperform
great start maintain outperform pt
updat confirm catalyst track
updat momentum build uniqu profil
review clinic execut intact acceler data
review readout vecabrutinib
report long-term trajectori remain track
report follow-up confer call
quick take
deliv record high revenu temper outlook reflect
pt
impact bill contract durat
wfh trend acceler need know strong
still drive double-digit ep growth
volum broadli impact headwind
pressur fleet/ota volum declin improv
trend better fear potenti
acceler offlin on-line shift maintain outperform
impact neutral positivegrowth outlook strong
promot list save raini day
fy advertis outlook better secular shift linear ott
increas expens disciplin partial recoveri market
 benefit hybrid rides/food structur
sheet flexibl critic increas pt
vg solid quarter mix guidanc decreas pt
benefit covid
opportun tough month april reiter outperform
strong quarter invest growth pull guidanc
bold move lead sustain profit
thought print adjust estim price
shift demand dynam posit
solid execut stori continu beyond
updat model result
wcn busi resili come fore rais pt
adjust estim reflect lower demand
io optim surviv choppi end-market
strateg initi remain track
review punch scotti pt
report financi updat brief investor busi preclin anim
early-stag human data provid regul reassur project good potenti
given get go-ahead start phase soon potenti start
earli summer potenti vaccin approv could happen truli warp speed drug develop project
import valuat cmv cancer vaccin etc also continu briskli testament compani mrna
platform manufactur scale invest inform technolog lead edg preclin clinic talent
took decad develop updat model increas pt stay bullish
va deliveri rais visibl biopharma backlog set rebound
disclos revenu beat forecast biopharma order report
segment revenu va deliv larg batch sampl april expect cover lab capac
end believ better visibl demand nearli compani diagnost univers
given sampl alreadi lab see limit downsid risk va revenu forecast manag comment
suggest biopharma order least cover forecast cumul biopharma revenu
furthermor view backlog increas continu addit new platform custom seven
evid acceler product accept
sustain growth resourc optim
solid execut nois
announc in-lin revenu downsid revis expect gm ep exclud one-tim tax benefit
compani also pull guidanc see uncertainti around project capit format certain custom well
risk project sale time compani continu show rel strong book price near-term custom
risk remain concern encourag commentari effici seri ramp potenti margin
expans retir seri capac understand compani limit suppli chain concern oper
vietnam malaysia facil full util ohio remain sidelin nt given project finance/project
time concern custom
move outperform price target
provid result busi updat increas confid time aro-aat open-label
data key readout view remain intact despit relat oper delay current valuat
believ stock leav meaning room upsid potenti aro-aat readout indic suppress mutant z-aat
protein product liver and/or lower level accumul polym post treatment therefor move
outperform rate perform price target addit view aro-aat remain well posit among
aatd-liv diseas candid believ next month may offer opportun assess clinic evid trim
cadenc recoveri reliant scienc higher margin
updat estim assum revenue/ep achiev level reflect multi-year recoveri
higher margin structur april newli book room-night year/year howev cancel
improv sinc peak mid-march stabil domest travel book countri eas lockdown
restrict howev visibl remain extrem limit difficult synthes current data definit trend mani
investor agre view flexibl high-margin cost structur strong liquid best posit lead travel
recoveri howev near-term see reliant viru treatment breakthrough vs large-cap internet
high-qual consum discretionari stock justifi case rel out-performance maintain perform
color fundament focu call
bound clinic reiter outperform
thursday report earn provid busi updat last week compani announc fda
clearanc ind first-in-human trial manag believ first patient could dose june
compani aim minim pandemic-rel delay initi util clinic site lightli affect
view ind clearanc mark major mileston develop could allow
present initi dose escal data estim compani suffici cash hand sustain oper
well beyond potenti clinic proof-of-concept reiter outperform rate pt
inhibitor readi despit pandem
thursday report earn spoke manag discuss recent progress march held
pre-nda meet fda final registr requir cgvhd base fda feedback
believ track submit nda consist prior guidanc manag late may
plan present six-month primari analysi pivot rockstar studi recal rockstar alreadi clear primari
efficaci endpoint two month focu six-month analysi respons durabl safeti although
led delay earlier-stag program believ compani cash posit sustain oper
reiter outperform pt
pandem may reset expect
thursday sere announc earn review recent progress cap enrol ecospor march
believ top-lin data could avail mid-to-l june view need safe demonstr
absolut reduct difficil infect cdi recurr rate satisfi regul less robust data could prompt fda
ask addit trial on-going trial includ eco-reset neg impact
disrupt patient recruit key assess could delay develop timelin manag
explor way expedit trial preserv data qualiti believ sere adequ cash sustain oper
potenti beyond de-risk data reiter outperform pt
thursday syro report earn discuss recent progress manag importantli
led materi delay compani clinic oper specif phase cohort evalu
azacitidin azac rara-posit r/r aml patient recent complet enrol remain track deliv proof-of-
concept result addit matur result azac newli diagnos aml cohort well initi phase
result focus safeti pk/pd expect becom avail later month syro plan
present new preclin data support develop colorect cancer adequ cash
potenti sustain oper reiter outperform rate pt
report leav mark
miragen report net loss vs estim seen number cover compani
mandat present headwind sever activ cobomarsen solar trial continu modifi
design execut encount challeng lack visibl readout time nonetheless believ case
expedit path market atll justifi fda meet like inform one-year keloid scar data
remlarsen may delay beyond due pandem impact clinic site bright spot view develop
ipf see expand preclin data ev believ pipelin progress
could spark interest
jelmyto june launch pad commerci strategi tailor time
report net loss lighter estim lower ahead jelmyto june commerci
entri groundwork laid drive urologist engag despit limit management indic
us urolog offic open treat patient submit applic specif c-code expect octob
perman code anticip ye project net sale mid-may see updat phase
data lg-ir nmibc present on-line aua phase commenc given share trade
ev believ posit upsid jelmyto becom prefer option lg utuc durabl benefit
evidenc follow compel interim respons rate
report modest trial pushout
net loss vs estim littl impact upon intern oper despit work
home polici mandat anticip clinic proof-of-concept result sever congenit neutropenia
pivot whim readout respect top-lin poc data waldenstrm remain track
look forward phase extens data whim virtual eha june suffici expans
debt facil provid addit capac reiter outperform
roughli expect ruc code still expect juli
irhythm report revenu y/i slightli ahead pre-announce our/consensu
estim increas home registr recal withdrew guid uncertainti
gross margin behind estim standard cost reset higher reserv lost patient
insur lower copay amid covid opex ex-verili estim bonu
stock comp reduct store new store sale new eagerli await cmss final rvu
determin still expect juli despit covid view whole stori predic rate shake
thought impact recoveri path
sale organ high-end pre-announc om y/
de-lever includ higher ou mix higher css sale saw strength
across neurosurgery/intern off-set instrument defer typic quarter-end purchas ott
impact procedur deferr regen orthoped april overal sale y/i
us/ou declin earli may trend show improv management conserv near-term growth
commentari evalu opening-up inpatient/icd bed neuro busi particular lever
potenti take slightli longer procedur come back result highli deferr give confid
procedure-recoveri
replant orchard maintain outperform
ortx provid result strateg updat includ meaning shift oper capit deploy
pipelin initi note manag plan expenditur close align launch product
demand refocus pipelin better leverag ortx hematopoet stem cell gene therapi platform across
broader rang indic larger address patient pool genet subset frontotempor dementia
crohn diseas patient favor dispos manag vision valu creation especi
effort imped near-term regulatori clinic catalyst mld maintain
outperform slightli lower pt vs remov revenu ada-scid reflect new oper
great start maintain outperform pt
maintain price target outperform rate follow teva result better
consensu revenu earn estim teva experienc increas volum potenti driven
stockpil manag note like trough quarter maintain guidanc note earli
sign gross oper margin improv driven manag preliminari implement execut margin-
optim plan remain bullish teva base improv bottom line driven factor within manag
updat confirm catalyst track
report result opex provid updat outlook key catalyst remain track
karxt schizophrenia registr path updat expect follow fda meet trial initi
anticip present addit data efficaci safeti includ analysi trae
rate adjunct set schizophrenia potenti new indic develop path updat expect
drp data healthi elderli volunt expect experiment pain data expect
recent initi coverag view karxt uniqu competit advantag larg market
opportun remain well-fund cash maintain outperform
updat momentum build uniqu profil
srra report financi result highlight progress anticip near-term catalyst srra initi pivot
momentum trial momelotinib continu open new studi site screen enrol patient certain
geographi depend circumst srra target symptomatic/anem mf patient previous
treat jak-inhibitor studi design demonstr benefit symptom reduct transfusion-independ
splenomegali vs danazol believ momelotinib larg opportun mf patient anemia srra plan
present addit data support anemia benefit view entre
eventu drive potenti util cash balanc last accord manag
review clinic execut intact acceler data
cellecti cll report result provid investor updat three clinic program
continu recruit/dos second dose level data present year-
end cll expect major impact dosing/enrollment/data readout three clinic project
current clinic drug suppli suffici cover least dose escal portion three trial construct
gmp manufactur site pari raleigh nc on-going track new hire dr carri brownstein
april see cll continu execut materi catalyst line updat model
earn stay bullish
review readout vecabrutinib
sunesi report financi result provid updat corpor progress vecabrutinib
phase result continu show encourag sign clinic activ cohort see momentum build toward
critic initi readout patient treat bid expect later quarter base prior dose cohort
encourag mosaic dose-rel activ emerg phase studi could posit
readout favor develop plan vecabrutinib potenti broaden look next step requir
logist develop financialmay lay ahead stay bullish
report ep opex cash month runway brillianc
trial first dose patient clear safeti hurdl allow dose next patient
follow dose next patient low-dos cohort mid-dos patient dose ind-en activ
plan start program preclin packag submit potenti licens oncolog
develop move forefront sever avenu partner cell program regain full right
non-alpha-beta cell focu innat immun system healthi donor-deriv nk cell tcell pluripot
report long-term trajectori remain track
report adj ep vs opco/street estim compani overcam
top-lin impact covid within hh pdgm top street expect larg driven cost
initi look forward management believ volum bottom hospic late hh earli hospic appear
larg recov prior run-rat alreadi home health referrals/admiss still approach pre-covid
level end april result slash ep estim maintain
ep note estim exclud contribut aseracar revenu expect close
report follow-up confer call
report adj-ep compar opco/street estim guidanc
though result met expect face soft educ busi saw revenue
impact earn impact due school closur meanwhil demand new busi face volatil rapidli
chang healthcar landscap lead compani provid guidanc due primarili uncertainti
lower ep estim maintain estim
quick take
report adj ep vs opco/street consensu estim compani
guidanc result solid due strong cost control visits-per-episod vs like peer
face impact pandem stretch hh growth march
impress fell return similarli
recent weekli data show admiss still level line trend competitor
though account smaller part busi hospic hcb fairli close pre-covid level
result uncertainti remov ep guidanc
deliv record high revenu temper outlook reflect uncertainti
post ahead consensu compani deliv
record-high revenu best-ev quarter north america result disrupt sever deal
close march compani expect sinc sign manag note continu
execut project key custom typic engag wide portfolio activ
maintain activ dialog execut view posit benefit shift digit
virtual network roll-out transform media pay-tv industri rise integr
carrier reiter outperform target
strong conserv guidanc given rais pt
rais price target net follow strong revenue/ep rev y/i
beat consensu although guidanc rais uncertainti keep guidanc
unchang rather rais encourag acceler new pay custom
yoy growth custom acv greater yoy solid momentum smb
ye smb grow yoy limit churn dollar-bas net retent rate remain strong continu
see net benefit grow internet traffic well need secur solut environ embrac wfh
report solid deliv upsid revenu ep cfo vs consensu estim nevertheless near-
term challeng healthcar segment emerg pandem divert doctors/med profession attent
away perform standard elect procedur drive usag henc lower guidanc highlight includ
dragon medic cloud powerscrib one one gain strong traction enterpris intellig engag
solut play critic role back custom contact center crisi dragon ambient experi
launch plan offer free dragon medic platform healthcar profession user
sign build goodwil custom balanc believ reacceler quickli abat
impact bill contract durat
report best consensu estim revenu margin ep howev contribut
bill soft anticip investor focu dynam shorten contract durat driven custom
tighten spend behavior favor shorter contract term takeaway includ wfh acceler demand email
protect casb brows isol dlp insid threat manag itm product sequenti declin
bill contract durat off-set asp gain improv discount trend expans opportun
grew y/i legaci displac on-premis incumb happen cloud migrat
cloud-bas revenu remain tailwind remain sidelin monitor progress
navig pandem perform
wfh trend acceler need know strong
report strong revenu y/i exceed street estim despit prior concern
iga solut see elong sale cycl complex implement phase would appear wfh grow
adopt acceler need address access element within corpor network henc
gener demand platform healthi trend persist april manag prudent withdrawn
guidanc given grow uncertainti associ remain posit hybrid infrastructur
approach grow subscript revenu contribut total support improv visibl level
believ reacceler revenu growth toward lt reiter pt base revenu
report result direct line mid-april pre-announc consid sharp coronaviru
headwind within merchant segment saw strong growth january/februari follow sharp slowdown toward
tail end march april social distanc lockdown measur implement global realiz
approxim y/i merchant volum declin april optimist recent seen sign volum
stabil acceler cost synergi goal implement increment short-term cost measur
remain optimist regard lt prospect share appear attract view revis ep
maintain outperform rate
still drive double-digit ep growth
impact late quarter drag post rel soft result y/i organ revenu growth
ep growth organ growth expectedli soft across segment consid drag late
march mainli impact accept payment longer provid outlook suggest line
sight double-digit ep growth impli notabl within accept busi volum improv
declin ldd declin recent meaning better peer trend also rais cost save
expect exit run-rat particular note announc ceo transit frank
bisignano succeed jeff yabuki effect juli mr yabuki enjoy extrem success tenur ceo
one best steward capit seen remain optimist long-term opportun particularli
fdc combin said drag present meaning drag near term maintain outperform
estim review
volum broadli impact headwind
fleetcor report rel soft result organ revenu growth vs estim howev
ep beat expect expect headwind impact growth broadli significantli fuel
card lodg segment grew y/i respect corpor payment busi realiz strong growth
toll provid outlook provid april updat expect revenu
declin y/i improv despit softer growth trend maintain ampl liquid
leverag remain well control ebitda maintain outperform rate estim review
pressur fleet/ota volum declin improv capit flexibl
report soft result continu weigh heavili travel volum fuel volumes/pric organ
revenu ex macro/acquisit increas y/i ep vs our/street estim volum trend
late-march/april fell significantli fleet travel respect april said continu
see strong momentum us busi realiz minim impact pandem also institut
near-term cost-cut measur provid expens save interestingli inform enett/
optal intend close previou acquisit agreement provid signific increment capit
flexibl maintain outperform rate lower pt
trend better fear potenti acceler offlin on-line shift maintain outperform
rais target maintain outperform rate april data trend much better fear april revenu
y/i vs street revenu y/i on-board sp reach record high april improv engag
exist sp non-discretionari job recov stronger discretionari job gmv recov modestli
indoor project delay see new custom mix suggest acceler shift on-line
invest fix price offer gear toward higher valu project track bookings/revenu trend
modestli ahead management expect though invest weigh near-term ebitda follow revenu outlook
repurchas fd float assum sale discount peer
impact neutral positivegrowth outlook strong promot list save raini day
increas target maintain outperform rate fvrr growth continu remain strong track
growth highlight strength decentr freelanc model sell smb revenu y/i
faster ttm activ buyer asp/buy acceler y/i respect march volatil
stabil yield six straight week acceler gmv growth april guid revenu midpoint
prior ahead street impli revenu y/i pull forward ebitda profit goal opex
leverag continu build market revenu germani austria saw record new
buyer spain seller new buyer m/m launch french-speak websit
fy advertis outlook better secular shift linear ott underway maintain outperform
follow report increas price target maintain outperform rate
advertis outlook better expect increas platform gross profit comp valuat
expand management expect substanti revenu growth y/i albeit slower pace advertis assum suggest
advertis y/i howev management give specif ad growth april caus assum weak trend
near-term revenu slow dramat reduc advertis sponsorship mani factor suggest roku/ott
emerg much stronger new account viewership surg especi avod linear-tv up-front
neg lock ad budget advertis want cancel linear-tv up-front delay cancel polici
loosen make real-tim programmat buy like
increas expens disciplin partial recoveri market benefit hybrid rides/food structur
increas target maintain outperform see meaning gain eat show
increas expens disciplin around busi lines/overal spend see partial recoveri market moreov
compani hybrid rides/food structur allow driver re-purpos keep user
engag use loyalti program potenti reduc market promot spend post pandem ride
global april though see wk/wk growth global last three week us bottom ride gb nyc
sf la chicago past week georgia/texa trough level hong kong back
pre-crisi level eat gb y/i april take-r improv q/q
cloud
report disappoint quarter sever key metric long-term trend look posit organ revenu growth
slump last quarter corpor revenu growth slump vs last year
corpor headwind includ largest sequenti chang usf tax rate year slowdown instal
thought stock expens go earn ebitda believ better entri point
stock could emerg posit continu take share busi wirelin low cost ip provid
cloud
follow fundament remain strong balanc sheet flexibl critic increas pt
earn manag call host ceo charl meyer cfo keith taylor come away import
takeaway valid pt increas first fundament pricing/book remain strong cloud/
internet custom scrambl highli interconnect datacent space meet surg usag
sudden increas demand posit datacent industri suppli long lead time second invest
grade rate help lower futur cost capit give compani flexibl pursu acquisitions/invest new metro
develop new product lastli believ investor underestim target new products/
geographi help sustain double-digit affo growth
cloud
vg solid quarter mix guidanc decreas pt
vonag revenu grew ex usf beat estim bp set slow highlight
api revenu y/i constant currenc vg gain traction market larger custom applic
servic ucaa contact center applic revenu grew y/i constant currenc led servic revenu
enterpris custom grew y/i guidanc weak manag conserv context
macro risk reduc pt base sotp analysi long term vg well-
posit busi forc digit transform meet demand continu enabl remot work forc
datatim may cloud-focus busi model benefit covid
earn recap fsli vg report strong result benefit busi digit post industry-
ration rapidli deploy sprint spectrum
egain report good march result assess consensu estim
busi immun disrupt caus good news abl quickli shift
work-from-hom oper top-of-the-funnel convers begun pick back balanc disrupt
like caus sale cycl elong instal base exposur riskier vertic travel retail etc
could pressur retent metric near term bottom line pandem creat good tailwind digit custom
engag technolog like organ look optim ineffici contact center workflow expos
crisi near term could bumpi like long-term opportun reiter outperform pt
payloc report better-than-fear earn guid despit realli bad unemploy data
posit result rel insul advers covid-rel effect manag report posit
book trend across smb midmarket custom lower financi target reduct activ
employe interest rate slow pace new client implement caus could continu bottom
line manag commentari employe reduct layoff consist smb hcm industri check
coincid spike us unemploy think upbeat new book commentari support valuat
sinc posit surpris howev remain sidelin prefer categori risk/reward
result busi outlook balanc strengthen secular opportun tough month april reiter
busi strong headwind subsequ manag good job protect
ebitda neg april platform spend declin y/i leav blemish among posit commentari
secular opportun strengthen bottom line earn updat offer someth everyon unlik
meaning chang opinion april commentari wors expect possibl trough month
behind busi current situat also benefit longer term compani competit moat
widen connectedtv programmat adopt acceler programmat oper environ shift
incumb advantag downturn setup point strong multi-year run stock potenti ad
spend growth return rais target
emerg technolog servic
strong quarter invest growth pull guidanc
axon report strong start year revenu well street estim manag gave new metric
custom retent announc first custom axon dispatch set record adj ebitda
adjust world rais money/suppli give emerg respond compani acknowledg
potenti deal pushout slowdown book polic budget becom strain howev management also indic
keep origin plan work toward year compromis compani pull annual guidanc
subscript part agenc oper budget help insul axon increas opex combin temporari
deceler top line stay sidelin
emerg technolog servic
bold move lead sustain profit
gopro provid detail direct-to-consum transform flagship devic primarili sold gopro com
direct consum mid- entry-level product select retail specialti store base profit strateg
locations/market opportun expans subscript offer detail like summer
drive gross margin higher opex lower run rate profit achiev unit sell nearli
previous fact model posit adj ebitda sale devic vs prior year
much uncertainti one thing certain strateg move need put gopro much firmer foot path
sustain strong profit
emerg technolog servic
despit pressur suppli chain turtl beach report above-guid quarterli result compani
abl meet call incred unexpect increas demand increas driven primarili
consum increas game time home shift school/work home shift video primari form
social engag strong video game titl activis call duti warzon nintendo anim cross
new horizon help give gamer reason upgrad although uncertainti remain maintain outperform rate
believ provid nice tailwind transit year thesi inflect higher sustain growth
new consol full effort pc expans remain intact
emerg technolog servic
identiv announc strong result driven primarili acceler demand smart card reader rfid record
backlog due work home measur compani continu focu expand recur revenu
y/i gross margin y/i economi normal manag believ compani
track acceler growth revenu recogn delay feder contract deliv opex reduc
opportun share gain well custom pull forward make perman wfh measur
thought print adjust estim price
recent sale trend comp begin improv unit reopen limit dine capac
exampl texa reopen capac weekli volum pace higher includ still elev level
off-premis sale analyz balanc sheet cash flow math see liquid issu follow recent equiti
transact revolv draw-down renegoti coven updat estim meaning lower reduc
price target
shift demand dynam posit
yesterday may market close outperform-r petiq report result updat investor
upon initi compani undertak manag on-going headwind us
continu tweak financi model plan publish updat spreadsheet soon
overal came away report quit impress encourag abil manag adjust
oper disciplin prospect compani capit upon forthcom post-coronaviru econom rebound
sale profit weak compani servic divis later first quarter seem entir tie onset
note key posit
demand product distribut manufactur sold partner retail store websit acceler consum
buy pattern shift amid pandem
data suggest compani servic divis apt benefit surg pent-up demand center start reopen soon
week
shift higher pet ownership us help underpin structur stronger product servic sale chain even
coronaviru disrupt gradual abat
report adj ep vs our/consensu estim miss driven lower anticip
margin weaker fpd fcd segment profit along higher corpor expens result includ approxim
impact defer revenu profit
withdrew financi guidanc april due uncertainti end market significantli
impact pandem oper meaning disrupt maintain solid balanc sheet total
liquid taken action right-siz oper current market environ opex
capital-expenditure reduct
solid execut stori continu beyond headwind
report adj ep vs our/consensu estim beat driven stronger
anticip margin particularli europ despit sporad plant closur manag withdrew full-year outlook due
uncertainti outlin assumpt challeng includ sale y/i oper margin
m/hsd rang proactiv adjust cost structur save variabl structur
action temporarili suspend share repurchas evalu initi necessari although anticip
signific near-term earn pressur y/i also expect repair/replace-weight demand stabil
late remain intrigu intermediate-term upsid smart connect roll-out look pullback
get construct share
report earn thursday sales/ep top revis street
shi origin pre-covid guid june outlook also top consensu led
smartphon ran management expect top-line contribut sale mgmt four recent acquisit
estim add increment top-line tailwind deal help off-set huawei-rel revenu loss
benefit rf content boost smartphon though expect growth water potenti delay
launch sale overal smartphon unit estim declin rais below-
street estim modestli see street trim temper expect trade war unresolv unit
volum uncertainti remain sidelin
highlight day alibaba chipmak arm grow strong digitim
demand car-us wafer impact pandem digitim
wi-fi chip vendor bullish rise end-market devic demand digitim
sustain growth resourc optim
updat model result
report sales/adj ep line see top-line margin pressur impact averag yield
tough comp prior year show price strength within report volum declin compani
call headwind lower rolloff commerci collect dispos revenu due viru wm
indic wednesday expect receiv final regulatori approv posit close acquisit
expect remain extend quiet period adjust forward estim updat industri expect
sustain growth resourc optim
announc record core earn beat consensu reiter fy guidanc report strong portfolio
perform qtd leverag debt equiti elev cash posit enhanc liquid provid ampl dri
powder toward manag expect origin opportun capit deploy remain divers
includ wind project rush complet well public-priv partnership ppp akin hawkey
deal look believ sustain infrastructur take new dimens built
environ requir invest measur protect occup health believ expand opportun set
partner reiter outperform rate
sustain growth resourc optim
wcn busi resili come fore rais pt
share trade thursday wcn beat top/bottom line consensu estim strong price growth underli
solid wast leverag provid illustr scenario base observ qtd organ trend potenti mix
impact bear watch balanc year see potenti favor decrement higher
convers remain lever upsid believ wcn market model continu support resili
returns/fcf macro uncertainti rais estim increas price target
sustain growth resourc optim
adjust estim reflect lower demand
post better expect earn power guid larg line updat street estim given
exposur consum electron energi vehicl sale industri product expect sale go multi-
quarter digest period social distanc measur eas believ compani suffici liquid continu
oper plan execut adjust capital-expenditure plan avoid costli shutdown/restart logist expect
low point revenu inventori lithium bromin busi work channel
peiod depress demand also model slower growth lower margin profil translat
reduct pt
sustain growth resourc optim
io optim surviv choppi end-market
wednesday close io publish result ahead top bottom line estim io report sale
y/i adjust ebitda larg driven increas multi-cli data librari
busi compani also announc cost reduct program order preserv cash manag liquid amid
on-going oil price crisi view resolut io westerngeco patent lawsuit well
divestitur jv bgp support io stabil go forward amid weak outlook believ io
asset-light strategi provid resiliencey flexibl navig potenti lumpi revenu evolv custom need
sustain growth resourc optim
continu execut long-term target succes complet refinanc expans
gener facil announc plan acquir technolog enabl comprehens solut hydrogen
fuel infrastrctur portfolio believ continu work custom reduc restrict cash balanc given
resili oper improv liquid posit believ compani may free cash use restrict cash
enabl acceller growth encourag see compani maintain guidanc believ valid
valu proposit facilit increas throughput warehous believ new custom interest increas
compani look opportun make oper cost effect
sustain growth resourc optim
strateg initi remain track
continu progress strateg initi indic spin-out maxeon remain track
would net transact time residenti dealer appear manag
downturn effect limit financi disturb believ bode well share busi rebound
social distanc measur eas continu target ramp storag product start understand
commerci busi make progress direct sale effort provid cash manag plan
includ proce sale share oper effici asset sale undrawn corpor revolv
remain sidelin given market uncertainti nt cash concern
sustain growth resourc optim
report solid result guid deploy larg line street expect oper
compani appear manag covid slowdown reason well believ investor look addit
clariti access capit understand compani near complet back leverag deal portfolio
asset provid addit liquid well expand avail tax equiti facil encourag
hear rate permit approv low-teen target market believ permit like prove
key bottleneck expect continu migrat on-line sale help pipelin growth remain
construct reiter
primarili due year extend ir deadlin due correspond shift tax file
see ir data outperform announc revenu expect
lower prior guidanc revenu adjust oper incom ep also expect lower due tax
season extens well advers impact affect compani small busi custom
withdraw guidanc reflect uncertainti current small busi trend notabl highlight
self-prepar tax file categori perform better tax professional-prepar file see ir data turbotax
on-line share within compani expect releas host correspond confer call
market close
ir releas weekli tax file data compar friday vs friday
weekli period total ir return received/tot e-fil receipt y/i respect ir
e-fil receipt tax profession declin y/i self-prepar e-fil receipt flat y/i
histor databas ir tax return file tax-compani on-line price avail upon request
year weekli period compar week week contain tax file deadlin
last year still significantli howev percentag y/i magnitud sever last week prior year
comparison period increas moder post-deadlin pace also notabl spread y/i declin
tax profession busi vs self-prepar return continu widen interpret like driven social
distanc due pandem
report adj ep vs estim line consensu beat primarili
driven higher expect top-lin revenu estim surprisingli compani indic market
condit hold deterior like accomplish guidanc year said believ
right long-term growth target opportun compel recess post
driven increas urgenc success plan need scale investor look recoveri stori
believ great bargain benefit unparallel long-term consolid trend ria industri
shutdown obvious caus lot challeng mani busi borrow nmfc
problem credit like bdc balanc manag great job earn call convinc us
larg preponder portfolio weather storm well convincingli display portfolio
grid show busi would impact impact impact a-c overal compani strength
manag qualiti pre-covid balanc sheet sponsor support exhibit sector greatest impact retail
health dental dermatolog eyecar portfolio roughli half group
may biotech summit featur chemistri life process institut chicago il virtual confer
